

Ref. No: 2491
Date: 02/04/26
Subject: Atopic Dermatitis

REQUEST & RESPONSE

Question 1. How many patients were treated in the last 4 months (December to March 2026) by the dermatology department with each of the following products:

- Abrocitinib
- Acitretin 20
- Alitretinoin
- Azathioprine 8
- Baricitinib 18
- Ciclosporin 72
- Dupilumab 141
- Lebrikizumab 7
- Methotrexate 514
- Mycophenolate mofetil 18
- Pimecrolimus 111
- Phototherapy (UVB or PUVA) - for Atopic Dermatitis only – unable to answer, Pharmacy don't have diagnosis data.
- Tacrolimus ointment 153
- Tralokinumab 8
- Upadacitinib 15
- Nemolizumab

Question 2. In the last 4 months, how many new patients have been initiated* on the following treatments by the dermatology department

- Abrocitinib
- Baricitinib
- Dupilumab >5
- Lebrikizumab
- Tralokinumab
- Upadacitinib <5
- Nemolizumab

Question 3. Of the patients treated in the last 4 months with any of the products listed in question 1, please provide the number of patients by the following age group:

- 6 months to 5
- Age 6-11
- Age 12-17
- Age 18 and above 938

Question 4. How many patients have received treatment by the dermatology department for Prurigo Nodularis in the last 4 months with each of the following products:

- Dupilumab
- Nemolizumab

Unable to answer Q4 as don't keep diagnosis information in Pharmacy